Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second lin...
Gespeichert in:
| Veröffentlicht in: | Journal of Cancer 2013-11, Vol.4 (9), p.736-754 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 754 |
|---|---|
| container_issue | 9 |
| container_start_page | 736 |
| container_title | Journal of Cancer |
| container_volume | 4 |
| creator | Domvri, Kalliopi Zarogoulidis, Paul Darwiche, Kaid Browning, Robert F Li, Qiang Turner, J Francis Kioumis, Ioannis Spyratos, Dionysios Porpodis, Konstantinos Papaiwannou, Antonis Tsiouda, Theodora Freitag, Lutz Zarogoulidis, Konstantinos |
| description | Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term "maintenance" treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials. |
| doi_str_mv | 10.7150/jca.7734 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3842443</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1540111270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-81b855d85c0ab23c3ee52567c886400d542bc017bc90eeb62f46384967d6aa413</originalsourceid><addsrcrecordid>eNpVkU1PAjEQhhujEYIk_gLTowfBfu12uZgoopKgJopH03S7AxSXLba7JPjrXSIizmUmmXeemcyL0CklXUkjcjk3uislFweoSRMuO704Fod7dQO1Q5iTOniPScGPUYMJThkVooneH10Opsq1x2Ptp1BChm99NQ1YFxm-sW6h_Qf4gG2Bn177o_4FLmeAByuXr2wxxS_1OHYTPCwyu7JZpXP7VSPGM_B6uT5BRxOdB2hvcwu93Q3G_YfO6Pl-2L8edQyXrOwkNE2iKEsiQ3TKuOEAEYtiaZIkFoRkkWCpIVSmpkcA0phNRMwT0YtlFmstKG-hqx_uskoXkBkoSq9ztfS2Pn-tnLbqf6ewMzV1K1VTmBC8BpxvAd59VhBKtbDBQJ7rAlwVFI0EoZQySf6kxrsQPEx2ayhRG0NUbYjaGFJLz_bP2gl_38-_AcHsheU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540111270</pqid></control><display><type>article</type><title>Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Domvri, Kalliopi ; Zarogoulidis, Paul ; Darwiche, Kaid ; Browning, Robert F ; Li, Qiang ; Turner, J Francis ; Kioumis, Ioannis ; Spyratos, Dionysios ; Porpodis, Konstantinos ; Papaiwannou, Antonis ; Tsiouda, Theodora ; Freitag, Lutz ; Zarogoulidis, Konstantinos</creator><creatorcontrib>Domvri, Kalliopi ; Zarogoulidis, Paul ; Darwiche, Kaid ; Browning, Robert F ; Li, Qiang ; Turner, J Francis ; Kioumis, Ioannis ; Spyratos, Dionysios ; Porpodis, Konstantinos ; Papaiwannou, Antonis ; Tsiouda, Theodora ; Freitag, Lutz ; Zarogoulidis, Konstantinos</creatorcontrib><description>Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term "maintenance" treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.7734</identifier><identifier>PMID: 24312144</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Review</subject><ispartof>Journal of Cancer, 2013-11, Vol.4 (9), p.736-754</ispartof><rights>Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-81b855d85c0ab23c3ee52567c886400d542bc017bc90eeb62f46384967d6aa413</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842443/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842443/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,862,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24312144$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Domvri, Kalliopi</creatorcontrib><creatorcontrib>Zarogoulidis, Paul</creatorcontrib><creatorcontrib>Darwiche, Kaid</creatorcontrib><creatorcontrib>Browning, Robert F</creatorcontrib><creatorcontrib>Li, Qiang</creatorcontrib><creatorcontrib>Turner, J Francis</creatorcontrib><creatorcontrib>Kioumis, Ioannis</creatorcontrib><creatorcontrib>Spyratos, Dionysios</creatorcontrib><creatorcontrib>Porpodis, Konstantinos</creatorcontrib><creatorcontrib>Papaiwannou, Antonis</creatorcontrib><creatorcontrib>Tsiouda, Theodora</creatorcontrib><creatorcontrib>Freitag, Lutz</creatorcontrib><creatorcontrib>Zarogoulidis, Konstantinos</creatorcontrib><title>Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term "maintenance" treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials.</description><subject>Review</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVkU1PAjEQhhujEYIk_gLTowfBfu12uZgoopKgJopH03S7AxSXLba7JPjrXSIizmUmmXeemcyL0CklXUkjcjk3uislFweoSRMuO704Fod7dQO1Q5iTOniPScGPUYMJThkVooneH10Opsq1x2Ptp1BChm99NQ1YFxm-sW6h_Qf4gG2Bn177o_4FLmeAByuXr2wxxS_1OHYTPCwyu7JZpXP7VSPGM_B6uT5BRxOdB2hvcwu93Q3G_YfO6Pl-2L8edQyXrOwkNE2iKEsiQ3TKuOEAEYtiaZIkFoRkkWCpIVSmpkcA0phNRMwT0YtlFmstKG-hqx_uskoXkBkoSq9ztfS2Pn-tnLbqf6ewMzV1K1VTmBC8BpxvAd59VhBKtbDBQJ7rAlwVFI0EoZQySf6kxrsQPEx2ayhRG0NUbYjaGFJLz_bP2gl_38-_AcHsheU</recordid><startdate>20131123</startdate><enddate>20131123</enddate><creator>Domvri, Kalliopi</creator><creator>Zarogoulidis, Paul</creator><creator>Darwiche, Kaid</creator><creator>Browning, Robert F</creator><creator>Li, Qiang</creator><creator>Turner, J Francis</creator><creator>Kioumis, Ioannis</creator><creator>Spyratos, Dionysios</creator><creator>Porpodis, Konstantinos</creator><creator>Papaiwannou, Antonis</creator><creator>Tsiouda, Theodora</creator><creator>Freitag, Lutz</creator><creator>Zarogoulidis, Konstantinos</creator><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20131123</creationdate><title>Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy</title><author>Domvri, Kalliopi ; Zarogoulidis, Paul ; Darwiche, Kaid ; Browning, Robert F ; Li, Qiang ; Turner, J Francis ; Kioumis, Ioannis ; Spyratos, Dionysios ; Porpodis, Konstantinos ; Papaiwannou, Antonis ; Tsiouda, Theodora ; Freitag, Lutz ; Zarogoulidis, Konstantinos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-81b855d85c0ab23c3ee52567c886400d542bc017bc90eeb62f46384967d6aa413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Domvri, Kalliopi</creatorcontrib><creatorcontrib>Zarogoulidis, Paul</creatorcontrib><creatorcontrib>Darwiche, Kaid</creatorcontrib><creatorcontrib>Browning, Robert F</creatorcontrib><creatorcontrib>Li, Qiang</creatorcontrib><creatorcontrib>Turner, J Francis</creatorcontrib><creatorcontrib>Kioumis, Ioannis</creatorcontrib><creatorcontrib>Spyratos, Dionysios</creatorcontrib><creatorcontrib>Porpodis, Konstantinos</creatorcontrib><creatorcontrib>Papaiwannou, Antonis</creatorcontrib><creatorcontrib>Tsiouda, Theodora</creatorcontrib><creatorcontrib>Freitag, Lutz</creatorcontrib><creatorcontrib>Zarogoulidis, Konstantinos</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Domvri, Kalliopi</au><au>Zarogoulidis, Paul</au><au>Darwiche, Kaid</au><au>Browning, Robert F</au><au>Li, Qiang</au><au>Turner, J Francis</au><au>Kioumis, Ioannis</au><au>Spyratos, Dionysios</au><au>Porpodis, Konstantinos</au><au>Papaiwannou, Antonis</au><au>Tsiouda, Theodora</au><au>Freitag, Lutz</au><au>Zarogoulidis, Konstantinos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2013-11-23</date><risdate>2013</risdate><volume>4</volume><issue>9</issue><spage>736</spage><epage>754</epage><pages>736-754</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term "maintenance" treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>24312144</pmid><doi>10.7150/jca.7734</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1837-9664 |
| ispartof | Journal of Cancer, 2013-11, Vol.4 (9), p.736-754 |
| issn | 1837-9664 1837-9664 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3842443 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Review |
| title | Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A45%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20Targeted%20Drugs%20and%20Biomarkers%20in%20NSCLC,%20the%20Evolving%20Role%20of%20Individualized%20Therapy&rft.jtitle=Journal%20of%20Cancer&rft.au=Domvri,%20Kalliopi&rft.date=2013-11-23&rft.volume=4&rft.issue=9&rft.spage=736&rft.epage=754&rft.pages=736-754&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.7734&rft_dat=%3Cproquest_pubme%3E1540111270%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1540111270&rft_id=info:pmid/24312144&rfr_iscdi=true |